Feldman, Sarah F.
Temkin, Elizabeth
Wulffhart, Liat
Nutman, Amir
Schechner, Vered
Shitrit, Pnina
Shvartz, Racheli
Schwaber, Mitchell J.
Carmeli, Yehuda
Article History
Received: 25 July 2022
Accepted: 10 November 2022
First Online: 23 November 2022
Declarations
:
: This study was approved by the Tel Aviv Sourasky Medical Center Institutional Review Board (#0307-21-TLV). The requirement for informed consent was waived for this study of de-identified, routinely collected surveillance data.
: Not applicable.
: YC has received grants from Pfizer and Shinogi; personal fees from Pfizer, Allecra, Nabriva therapeutics, Roche, Genetech, Qpex biopharma, and Merck Sharpe & Dohme; and is on the Data Safety Monitoring Board or Advisory Board of Pfizer, Merck Sharpe & Dohme, Venatorx pharmaceuticals, and Enlivex therapeutics, outside the submitted work. All other authors declare no competing interests.